uniQure's stock price has experienced significant fluctuations, with reports of a surge following FDA clearance for a gene therapy and the company meeting goals in a Huntington's disease study. However, there are also reports of the stock crashing by a substantial percentage over a short period. The stock's overall trajectory and potential for further upside or decline are uncertain, with various outlets offering different predictions and analyses.